TG Therapeutics shares surged 11.6% to $31.10 following the announcement of a preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million.
The strong financial performance, despite a broader market decline with the Nasdaq Composite falling over 200 points, showcases TG Therapeutics' competitiveness in the biopharmaceutical sector. The preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
This optimistic outlook is expected to boost shareholder confidence and attract more capital inflow, positioning TG Therapeutics favorably in a challenging market environment.
Wall Street analysts forecast ADNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADNT is 23.06 USD with a low forecast of 20.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ADNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADNT is 23.06 USD with a low forecast of 20.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
5 Hold
1 Sell
Hold
Current: 21.060
Low
20.00
Averages
23.06
High
28.00
Current: 21.060
Low
20.00
Averages
23.06
High
28.00
Stifel
Buy
maintain
$24 -> $26
2026-01-23
Reason
Stifel
Price Target
$24 -> $26
AI Analysis
2026-01-23
maintain
Buy
Reason
Stifel raised the firm's price target on Adient to $26 from $24 and keeps a Buy rating on the shares as part of the firm's Q4 preview for its diversified industrials coverage.
Barclays
Equal Weight
maintain
$24 -> $25
2026-01-23
Reason
Barclays
Price Target
$24 -> $25
2026-01-23
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Adient to $25 from $24 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the autos and mobility group as part of a Q4 preview. Barclays continue to prefer the car markers, saying they are benefiting from "healthy" production rates and reduced electric vehicle losses.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADNT
Unlock Now
Morgan Stanley
Underweight -> Equal Weight
upgrade
$410 -> $425
2025-12-08
Reason
Morgan Stanley
Price Target
$410 -> $425
2025-12-08
upgrade
Underweight -> Equal Weight
Reason
Morgan Stanley upgraded Adient to Equal Weight from Underweight with a price target of $425, up from $410, following a change in analysts. The firm adjusted ratings in the autos and shared mobility group as part of its 2026 outlook. Morgan Stanley is "leaning more cautious" into next year, saying the electric vehicle "winter" will sustain through 2026. This is counterbalanced by a "moderately more positive" outlook on internal combustion engines and hybrids, the analyst tells investors in a research note.
Citi
Michael Ward
Neutral
downgrade
$25
2025-11-12
Reason
Citi
Michael Ward
Price Target
$25
2025-11-12
downgrade
Neutral
Reason
Citi analyst Michael Ward lowered the firm's price target on Adient to $22.50 from $25 and keeps a Neutral rating on the shares.
About ADNT
Adient PLC is an automotive seating supplier company. The Company’s automotive seating solutions include complete seating systems, frames, mechanisms, foam, head restraints, armrests and trim covers. The Company designs, manufactures and markets a full range of seating systems and components for passenger cars, commercial vehicles and light trucks, including vans, pick-up trucks and sport/crossover utility vehicles. The Company manages its business on a geographic basis and operates in three reportable segments: Americas, which is inclusive of North America and South America; Europe, Middle East, and Africa (EMEA), and Asia Pacific/China (Asia). The Company operates approximately 200 wholly- and majority-owned manufacturing or assembly facilities, with operations in approximately 29 countries. The Company provides production and service parts to its customers under multi-year programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
